×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [8]
湖南大学 [1]
合肥物质科学研究院 [1]
内容类型
期刊论文 [10]
发表日期
2022 [1]
2021 [4]
2019 [1]
2017 [1]
2016 [1]
2015 [2]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共10条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Repressing MYC by targeting BET synergizes with selective inhibition of PI3K alpha against B cell lymphoma
期刊论文
CANCER LETTERS, 2022, 卷号: 524, 页码: 206-218
作者:
Chen, Zi-qi
;
Cao, Zhe-rui
;
Wang, Yi
;
Zhang, Xi
;
Xu, Lan
收藏
  |  
浏览/下载:53/0
  |  
提交时间:2021/12/16
CYH33
MYC
P300
BET
B cell lymphoma
PI3K
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K delta inhibitor idelalisib
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 13
作者:
Zhou, Xiao-ru
;
Li, Xiao
;
Liao, Li-ping
;
Han, Jie
;
Huang, Jing
收藏
  |  
浏览/下载:30/0
  |  
提交时间:2021/06/11
mantle cell lymphoma
idelalisib
drug resistance
P300
CBP
synergistic drug action
PI3Kδ
epigenetics
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K delta inhibitor idelalisib
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 13
作者:
Zhou, Xiao-ru
;
Li, Xiao
;
Liao, Li-ping
;
Han, Jie
;
Huang, Jing
收藏
  |  
浏览/下载:27/0
  |  
提交时间:2021/06/11
mantle cell lymphoma
idelalisib
drug resistance
P300
CBP
synergistic drug action
PI3Kδ
epigenetics
SAF-248, a novel PI3K delta-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 11
作者:
Zhang, Xi
;
Duan, Yu-ting
;
Wang, Yi
;
Zhao, Xing-dong
;
Sun, Yi-ming
收藏
  |  
浏览/下载:35/0
  |  
提交时间:2021/05/24
PI3Kδ
PI3K
AKT
mTOR
diffuse large B-cell lymphoma
resistance
combination therapy
PI3K alpha inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8(+)T cells and promoting fatty acid metabolism
期刊论文
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 卷号: 9, 期号: 8, 页码: 16
作者:
Sun, Pu
;
Zhang, Xi
;
Wang, Rong-Jing
;
Ma, Qing-Yang
;
Xu, Lan
收藏
  |  
浏览/下载:42/0
  |  
提交时间:2021/11/04
tumor microenvironment
immunomodulation
immunologic memory
lymphocytes
tumor-infiltrating
macrophages
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
期刊论文
International journal of cancer, 2019
作者:
Sophia Stock
;
Rudolf Übelhart
;
Maria-Luisa Schubert
;
Fuli Fan
;
Bailin He
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2019/12/13
Phosphatidylinositol
3-kinase
(PI3K)
chimeric
antigen
receptor
(CAR)
chronic
lymphocytic
leukemia
idelalisib
immunotherapy
SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3K delta) inhibitors
期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 125, 页码: 1156-1171
作者:
Wei, Manman
;
Zhang, Xi
;
Wang, Xiang
;
Song, Zilan
;
Ding, Jian
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2019/01/08
Chronic lymphocytic leukemia
PI3K delta
Structure-activity relationship
5-Alkynyl
Quinazolinone
Characterization of selective and potent PI3K delta inhibitor (PI3KD-IN-015) for B-Cell malignances
期刊论文
ONCOTARGET, 2016, 卷号: 7, 期号: 22, 页码: 32641-32651
作者:
Liu, Xiaochuan
;
Wang, Aoli
;
Liang, Xiaofei
;
Chen, Cheng
;
Liu, Juanjuan
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2017/11/16
Pi3k Delta
Leukemia
B-cell Malignances
Pi3k
Kinase Inhibitors
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
期刊论文
ACTA PHARMACOLOGICA SINICA, 2015, 卷号: 36, 期号: 10, 页码: 1170-1176
作者:
Wang, Xiang
;
Ding, Jian
;
Meng, Ling-hua
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2019/01/08
PI3K isoforms
isoform-selective inhibitor
CAL101
precise cancer therapy
biomarker
Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond
期刊论文
MEDICINAL RESEARCH REVIEWS, 2015, 卷号: 35, 期号: 4, 页码: 720-752
作者:
Wei, Manman
;
Wang, Xiang
;
Song, Zilan
;
Jiao, Mingkun
;
Ding, Jian
收藏
  |  
浏览/下载:18/0
  |  
提交时间:2019/01/08
chronic lymphocytic leukemia
PI3K
inhibitor
molecularly targeted therapy
idelalisib
©版权所有 ©2017 CSpace - Powered by
CSpace